Home/Hedge Fund Intelligence/Protagonist Therapeutics, Inc
Nasdaq: PTGXStockForm 13F30 Jun 2026

Hedge funds that hold Protagonist Therapeutics, Inc Nasdaq: PTGX

CUSIP 74366E102 · who reports it, how much, and how much it matters to them

29 of the 720 hedge fund managers we track reported shares of Protagonist Therapeutics, Inc (Nasdaq: PTGX) on Form 13F for 30 June 2026. Between them they reported USD 1.7bn. The largest position belongs to Farallon Capital Management, at USD 778m. The manager with the most riding on it is RTW Investments, where it is 5.3% of the reported book.

Managers reporting it29of 720 we track
Value they reportUSD 1.7bnshares only, 30 Jun 2026
Funds they run444with a file on PPLI.com
Largest positionUSD 778mFarallon Capital Management
Typical weight0.0%median share of a manager's book
Heaviest weight5.3%RTW Investments

Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated

Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.

13F
What this page is

A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.

Who holds it

29 managers, USD 1.7bn between them

Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.

Every manager that reports Protagonist Therapeutics, Inc, largest position first

The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.

#ManagerValue reportedShare of its book
1Farallon Capital Management56 funds on PPLI.comUSD 778m3.6%
2RTW Investments2 funds on PPLI.comUSD 620m5.3%
3Perceptive Advisors6 funds on PPLI.comUSD 120m1.8%
4683 Capital Management2 funds on PPLI.comUSD 36m1.7%
5Eagle Health Investments1 fund on PPLI.comUSD 30m5.0%
6Boxer Capital Management1 fund on PPLI.comUSD 21m1.6%
7Marshall Wace LLP84 funds on PPLI.comUSD 13m0.0%
8Atika Capital Management3 funds on PPLI.comUSD 7.6m0.5%
9Eversept Partners3 funds on PPLI.comUSD 7.2m0.4%
10Orbimed Advisors1 fund on PPLI.comUSD 5.2m0.1%
11LMR Partners2 funds on PPLI.comUSD 4.7m0.0%
12Schonfeld Strategic Advisors30 funds on PPLI.comUSD 3.4m0.0%
13Brevan Howard Capital Management39 funds on PPLI.comUSD 3.1m0.0%
14HighVista Strategies27 funds on PPLI.comUSD 3m0.7%
15Artia Global Partners1 fund on PPLI.comUSD 2.8m0.5%
16Weiss Asset Management5 funds on PPLI.comUSD 1.7m0.0%
17Aquatic Capital Management3 funds on PPLI.comUSD 1.5m0.1%
18Verition Fund Management3 funds on PPLI.comUSD 1.2m0.0%
19J. Goldman & Co.1 fund on PPLI.comUSD 1.2m0.0%
20Bridgewater Associates45 funds on PPLI.comUSD 1.1m0.0%
21Holocene Advisors2 funds on PPLI.comUSD 1m0.0%
22Campbell & Company Investment Adviser8 funds on PPLI.comUSD 761,0000.0%
23Engineers Gate Manager1 fund on PPLI.comUSD 536,0000.0%
24Balyasny Asset Management25 funds on PPLI.comUSD 441,0000.0%
25Bayforest Capital1 fund on PPLI.comUSD 328,0000.3%
26CIBC Asset Management69 funds on PPLI.comUSD 242,0000.0%
27Graticule Asia Macro Advisors8 funds on PPLI.comUSD 31,8710.0%
28Fulcrum Asset Management LLP7 funds on PPLI.comUSD 5,5950.0%
29Walleye Capital8 funds on PPLI.comUSD 1230.0%
Next: where it matters most
Where it matters most

For RTW Investments it is 5.3% of the book

A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.

#ManagerValue reportedShare of its book
1RTW InvestmentsUSD 620m5.3%
2Eagle Health InvestmentsUSD 30m5.0%
3Farallon Capital ManagementUSD 778m3.6%
4Perceptive AdvisorsUSD 120m1.8%
5683 Capital ManagementUSD 36m1.7%
6Boxer Capital ManagementUSD 21m1.6%
7HighVista StrategiesUSD 3m0.7%
8Artia Global PartnersUSD 2.8m0.5%
9Atika Capital ManagementUSD 7.6m0.5%
10Eversept PartnersUSD 7.2m0.4%
Next: how to read this
How to read this

What a 13F list can and cannot tell you

  • It is the manager's filing, not a fund's. Form 13F covers every account a firm runs. We cannot say which of its funds holds the shares.
  • It is a snapshot. The list shows the last day of the quarter. A manager may have bought or sold since, and trading inside the quarter leaves no trace.
  • It shows one side. Short positions, swaps and shares listed outside the United States are not reported, so a manager on this list may be hedged or net short.
  • It covers the managers we track. Our coverage is 720 managers of hedge and private funds. Banks, index funds and other institutions that file Form 13F are not counted here.
Next: questions
Questions

Questions about who holds Protagonist Therapeutics, Inc

What is the ticker symbol of Protagonist Therapeutics, Inc?

Protagonist Therapeutics, Inc trades under the symbol PTGX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 74366E102.

Which hedge funds own Protagonist Therapeutics, Inc (Nasdaq: PTGX)?

29 of the 720 hedge fund managers PPLI.com tracks reported Protagonist Therapeutics, Inc shares on Form 13F for 30 June 2026. The largest reported positions were held by Farallon Capital Management (USD 778m), RTW Investments (USD 620m), Perceptive Advisors (USD 120m), 683 Capital Management (USD 36m) and Eagle Health Investments (USD 30m).

How many hedge funds hold Protagonist Therapeutics, Inc?

29 managers in our coverage reported it, and between them they run 444 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.

Which manager has the most riding on Protagonist Therapeutics, Inc?

RTW Investments, where the position was 5.3% of the reported 13F book at 30 June 2026.

Does this show who is short Protagonist Therapeutics, Inc?

No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.

Important information

Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Protagonist Therapeutics, Inc or with the managers listed.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.

Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.